TC Therapeutics (PTCT) failed to convince a panel of FDA-appointed experts that its Duchenne muscular dystrophy drug Translarna was worthy of approval.

By a 10-1 vote, the FDA advisory panel concluded that while Translarna might be effective, the data submitted by PTC were inconclusive, and more work was needed to establish the drug’s efficacy. The sole dissenting vote to approve the drug now came from a panel member with a child with DMD.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.